Abstract
<h2>Abstract</h2> This paper examines the potential of progesterone antagonists for treating hormone dependent breast cancer, as judged from experimental studies. The original lead compound, Ru (38)486 (Mifepristone), was intended originally to be an antiglucocorticoid. It is apparent that there are pregnancy-related indications for this compound. For the much newer more specific compounds there are several tumour indications. The growth inhibitory efficacy of a prosgesterone antagonist was compared with different endocrine treatment regimens in the MNU-induced mammary carcinoma model. Long-term treatment with onapristone achieved the most effective inhibition of tumour growth. In a second-line treatment regimen, after 3 weeks pretreatment with tamoxifen, the effectiveness of onapristone on tumour growth was equal with the efficacy of medroxyprogesterone acetate. The efficacy of a combined treatment of a progesterone antagonist and a `pure' antioestrogen (ICI 164.384) was investigated in the MXT mouse mammary carcinoma. The combined treatment was more effective than oophorectomy. Tumour inhibition induced by progesterone antagonists appears to be associated with the induction of apoptosis.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
